Nova Eye Medical Ltd (ASX: EYE) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Nova Eye Medical Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$31.34 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
284.88 million
Earnings per share
-0.025
Dividend per share
N/A
Year To Date Return
-13.21%
Earnings Yield
N/A
Franking
100%
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Nova Eye Medical Ltd (ASX: EYE)
Latest News
⏸️ Investing
3 exciting small cap healthcare shares to buy today
⏸️ Investing
Why these 4 ASX shares started the week higher
⏸️ Investing
Top stock picks for December
⏸️ Investing
3 companies positioned to win big in 2018
⏸️ Investing
5 shares you need to watch on Tuesday
⏸️ Investing
2 top healthcare companies I'm watching like a hawk
⏸️ Investing
Top stock picks for September
⏸️ Investing
Why these 4 ASX shares are ending the week deep in the red
⏸️ Investing
3 little known companies I'm watching like a hawk
⏸️ Investing
3 ASX shares at 52-week lows: Are they bargain buys?
⏸️ Investing
Why these 4 ASX shares are ending the week deep in the red
⏸️ Investing
Why the Ellex Medical Lasers Limited share price fell 14% today
Dividend Payment History Data provided by Morningstar.
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| 21 Jul 2020 | $0.1350 | 100.00% | Special Cash | 29 Jul 2020 |
EYE ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Nova Eye Medical Ltd
Nova Eye Medical Ltd. engages in developing suite of novel ophthalmic treatment technologies. It operates through the following segments: Faster Growing (iTrack), Emerging (2RT), and Core Ophthalmic Mark (Lasers and Ultrasounds). The iTrack segment offers catheter device that dilates the ocular structures compromised by glaucoma. The 2RT segment includes patent-protected with significant lead on competition and a per-use recurring fee business model. The Lasers and Ultrasounds segment represents testimony to the strength of the Ellex brand and was driven by growth in sales of the high-margin Ellex Tango and Ellex Tango Reflex glaucoma lasers. The company was founded by Giuseppe Canala and Victor Previn in 1985 and is headquartered in Kent Town, Australia.
EYE Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 15 Jul 2026 | $0.11 | $-0.01 | -8.70% | 44,000 | $0.11 | $0.11 | $0.11 |
| 13 Jul 2026 | $0.12 | $0.00 | 0.00% | 594 | $0.12 | $0.12 | $0.12 |
| 10 Jul 2026 | $0.12 | $0.01 | 9.09% | 30,549 | $0.12 | $0.12 | $0.12 |
| 09 Jul 2026 | $0.11 | $0.00 | 0.00% | 54,775 | $0.11 | $0.11 | $0.11 |
| 08 Jul 2026 | $0.11 | $0.00 | 0.00% | 104,848 | $0.11 | $0.11 | $0.11 |
| 07 Jul 2026 | $0.11 | $0.01 | 9.52% | 384,060 | $0.11 | $0.11 | $0.11 |
| 06 Jul 2026 | $0.11 | $0.00 | 0.00% | 52,811 | $0.12 | $0.12 | $0.11 |
| 03 Jul 2026 | $0.11 | $-0.01 | -9.09% | 41,769 | $0.11 | $0.12 | $0.11 |
| 02 Jul 2026 | $0.11 | $0.00 | 0.00% | 68,353 | $0.11 | $0.11 | $0.11 |
| 01 Jul 2026 | $0.11 | $0.01 | 9.52% | 62,399 | $0.11 | $0.11 | $0.11 |
| 30 Jun 2026 | $0.11 | $0.00 | 0.00% | 718,965 | $0.11 | $0.11 | $0.10 |
| 29 Jun 2026 | $0.10 | $0.00 | 0.00% | 438,023 | $0.11 | $0.11 | $0.10 |
| 26 Jun 2026 | $0.11 | $0.00 | 0.00% | 125,117 | $0.11 | $0.11 | $0.11 |
| 25 Jun 2026 | $0.10 | $0.00 | 0.00% | 371,770 | $0.10 | $0.11 | $0.10 |
| 24 Jun 2026 | $0.10 | $0.00 | 0.00% | 322,318 | $0.11 | $0.11 | $0.10 |
| 23 Jun 2026 | $0.11 | $0.00 | 0.00% | 1,116,796 | $0.11 | $0.11 | $0.10 |
| 22 Jun 2026 | $0.11 | $0.00 | 0.00% | 183,813 | $0.11 | $0.11 | $0.11 |
| 19 Jun 2026 | $0.11 | $-0.01 | -8.70% | 392,630 | $0.11 | $0.11 | $0.11 |
| 18 Jun 2026 | $0.12 | $0.00 | 0.00% | 205,441 | $0.11 | $0.12 | $0.11 |
| 17 Jun 2026 | $0.12 | $0.00 | 0.00% | 653,688 | $0.12 | $0.12 | $0.11 |
| 16 Jun 2026 | $0.12 | $0.00 | 0.00% | 42,217 | $0.12 | $0.12 | $0.12 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 01 Sep 2025 | Thomas (Tom) Spurling | Buy | 78,273 | $11,740 |
Off-market trade.
|
| 04 Aug 2025 | Thomas (Tom) Spurling | Issued | 300,000 | $45,000 |
Conversion of securities.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Victor Previn | Executive DirectorExecutive Chairman | Jul 2001 |
Mr Previn is a professional engineer and one of the original founders of the Company. His career spans more than 40 years in both the ophthalmic laser industry and the wider ophthalmic device sector. Mr Previn was elected Chairman of the Board of Directors. He is also a member of the Risk Committee.
|
| Mr Thomas (Tom) Anthony Spurling | Managing Director | Aug 2020 |
Mr Spurling has 30 years of senior executive experience serving in a range of commercial and management roles in Australia and the United States.
|
| Mr Rahmon Coupe | Non-Executive Director | May 2013 |
Mr Coupe has 37 years of experience in the areas of corporate management, intellectual property management, contract negotiation, business development and engineering and has worked across a range of industries, including information technology, life sciences and public broadcasting. He is currently a member of the Risk Committee.
|
| Mr Mike Southard | Executive Director | Jul 2018 |
Mr Southard spent 26 years with Alcon Laboratories of Fort Worth, Texas, as Vice President of the Global Surgical business. Prior to this, he was an Executive with Beecham Laboratories (now SmithKline Beecham), and Cooper-Vision, which was acquired by Alcon Laboratories. Mike is currently actively involved in ophthalmology, dermatology and orthopaedics through his consulting company based in Portland, Oregon, USA. He has experience in both the International and US markets.
|
| Mr Daniel Webb | Non-Executive Director | Nov 2022 |
Mr Webb is based in Toronto, Canada and has a career that has spanned over 40 years in the marketing, sale and distribution of medical devices. After spending 10 years in various positions in ophthalmic device sales, Dan commenced his career with the medical laser company Coherent. In 1990 Dan established Coherent-AMT, now known as Clarion Medical Technologies (Clarion) to import, market, sell and distribute a range of medical devices, focusing on ophthalmic, aesthetic and surgical devices, in Canada.
|
| Mr Simon Ramsey Alexander Gray | Company Secretary | Jun 2020 |
-
|
| Simon Ramsey Alexander Gray | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| HSBC Custody Nominees (Australia) Limited | 52,624,920 | 18.48% |
| J P Morgan Nominees Australia Pty Limited | 10,446,115 | 3.67% |
| Sedico Pty Ltd <Victor Previn Family A/C> | 7,945,355 | 2.79% |
| Ruminator Pty Ltd | 5,694,759 | 2.00% |
| Canala Super Fund Pty Ltd <Giuseppe Canala Sf A/C> | 4,515,857 | 1.59% |
| Highlands Investments Holdings Pty Ltd | 3,600,113 | 1.26% |
| Sean Barrett Pty Ltd <Super Fund A/C> | 3,526,847 | 1.24% |
| Citicorp Nominees Pty Limited | 3,433,696 | 1.21% |
| Dinwoodie Investments Pty Ltd | 3,105,954 | 1.09% |
| Mr Campbell Dinwoodie Taylor & Miss Sarah Joan Curtis <Cambet Super Fund A/C> | 2,718,318 | 0.95% |
| Super Wide Pty Ltd <Super Wide Super Fund A/C> | 2,689,831 | 0.94% |
| Sedico Pty Ltd <Victor Previn Superfund A/C> | 2,258,373 | 0.79% |
| Mr Robert Min | 2,167,262 | 0.76% |
| Mrs Glenis Nita O'Donnell | 2,060,000 | 0.72% |
| Super Success Pty Ltd <Super Success Fam Super A/C> | 2,050,000 | 0.72% |
| BNP Paribas Nominees Pty Ltd <HUB24 Custodial Serv Ltd> | 2,043,910 | 0.72% |
| Mr Maximilian Django Jacobson Rudd | 2,000,000 | 0.70% |
| Mr Robert Brydon Rudd | 1,950,000 | 0.68% |
| Sharesies Australia Nominee Pty Limited | 1,871,789 | 0.66% |
| BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient> | 1,847,751 | 0.65% |
